bcdiabetes.ca
Patient Care + Research + Clinical Trials

Dr. Tom Elliott MBBS, FRCPC
Medical Director

400 - 210 W Broadway
Vancouver, BC
V5Y 3W2 Canada

phone: 604.683.3734
fax: 604.628.3821
email: moa@bcdiabetes.ca

AZ Cotadutide Renal Trial

Study location: BCDiabetes: 400 - 210 West Broadway, Vancouver V5Y 3W2
Principal Investigators Dr. Tom Elliott
Study coordinator & primary contact Dr. Marla Inducil P: 604-628-7253 x 7011 : minducil@bcdiabetes.ca

Summary:
Cotadutide Renal Outcome Trial is A Phase 2b, Multicentre, Randomised, Double-blind, Placebo-controlled, and Open-label Comparator Study of Cotadutide in Participants Who Have Chronic Kidney Disease with Type 2 Diabetes Mellitus

Eligible Participants include:

- Male or female aged 8-79 years
- eGFR 20-89 UACR > 5.7 mg/mmol
- A1c 6.5-12.5%
- BMI > 25
- On ACEi or ARB

Treatment course and duration:
This is a randomised, double-blind, placebo-controlled, and open-label comparator study to evaluate the efficacy, safety, tolerability, and PK profile of cotadutide uptitrated from 50 to 100, 300, or 600 µg administered subcutaneously (SC) once daily over 26 weeks in participants who have CKD with T2DM (eGFR ≥ 20 and < 90 mL/min/1.73 m 2 and micro- or macroalbuminuria). Placebo will be matched to cotadutide. The open-label comparator, semaglutide, will be administered subcutaneously (SC) from 0.25 to 1.0 mg once weekly over 26 weeks. Cotadutide, placebo, and semaglutide will be administered using an injection pen device.
Odds of receiving placebo:
The odds of receiving placebo are ⅕ (20%). The odds of receiving teplizumab are 3/5(60%). The odds of receiving semaglutide is ⅕ (20%)
Other Notes:
CGM provided; visits every 2 weeks for 28 weeks

Short URL = https://bit.ly/3lJAjT5